par Sims, Emily EK;Evans-Molina, Carmella;Tersey, Sarah SA;Eizirik, Decio L. 
;Mirmira, Raghavendra R.G.
Référence Diabetologia, 61, 11, page (2259-2265)
Publication Publié, 2018
;Mirmira, Raghavendra R.G.Référence Diabetologia, 61, 11, page (2259-2265)
Publication Publié, 2018
Article révisé par les pairs
| Résumé : | Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there is a need for robust biomarkers of beta cell health, which could provide insight into pathophysiological differences in disease course, improve disease prediction, increase the understanding of therapeutic responses to immunomodulatory interventions and identify individuals most likely to benefit from these therapies. In this review, we outline current literature, limitations and future directions for promising circulating markers of beta cell stress and death in type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs and circulating DNAs. |
